PMID- 38058831
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231208
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 11
DP  - 2023
TI  - Integrated multiplex network based approach reveled CC and CXC chemokines 
      associated key biomarkers in colon adenocarcinoma patients.
PG  - 5531-5548
AB  - Colon adenocarcinoma (COAD) is a prevalent and aggressive form of cancer that 
      necessitates the identification of robust biomarkers for early diagnosis and 
      treatment. Therefore, this project was launched to identify a few key biomarkers 
      from CC and CXC chemokine families for the accurate detection of COAD. Hub gene 
      identification was performed using CytoHubba analysis. Clinical samples from COAD 
      patients and normal individuals were collected and subjected to appropriate 
      methods for DNA and RNA extraction. The expression levels of hub genes were 
      analyzed using reverse transcription-quantitative polymerase chain reaction 
      (RT-qPCR), while promoter methylation analysis was conducted using targeted 
      bisulfite sequencing (bisulfite-seq). Additionally, The Cancer Genome Atlas 
      (TCGA) and Gene Expression Omnibus (GEO) datasets were utilized to validate the 
      findings based on clinical samples. CXCL10 (C-X-C motif chemokine ligand 10), 
      CXCL12 (C-X-C motif chemokine ligand 12), CXCL16 (C-X-C motif chemokine ligand 
      16), and CCL25 (CC motif chemokine ligand 25) were denoted as the key hubs among 
      CC and CXC chemokine families. Through RT-qPCR analysis, it was found that 
      CXCL10, CXCL12, and CXCL16 were significantly up-regulated, while CCL25 was 
      down-regulated in COAD patients compared to healthy controls. Later on, these 
      findings were also validated using TCGA and GEO datasets consisting of COAD and 
      normal control samples. Furthermore, we investigated the promoter methylation 
      status of these chemokine genes in COAD patients. Our results revealed 
      significant dysregulation of promoter methylation, suggesting an epigenetic 
      mechanism underlying the altered expression of CXCL10, CXCL12, CXCL16, and CCL25 
      in COAD. In addition to this, various additional aspects of the CCL25, CXCL10, 
      CXCL12, and CXCL16 have also been uncovered in COAD during the present study. 
      This study highlights the dysregulation of CXCL10, CXCL12, CXCL16, and CCL25 
      chemokine members in COAD patients, emphasizing their significance as potential 
      biomarkers and therapeutic targets in the management of this deadly disease. 
      However, further investigations are warranted to elucidate the underlying 
      molecular mechanisms and evaluate the clinical utility of these findings.
CI  - AJCR Copyright (c) 2023.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing 
      University of Chinese Medicine Nanjing, Jiangsu, China.
AD  - Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated 
      Hospital of Nanjing University of Chinese Medicine Nanjing, Jiangsu, China.
FAU - Hu, Yanyan
AU  - Hu Y
AD  - Jiangsu Provincial Hospital of Chinese Medicine Affiliated to Nanjing University 
      of Chinese Medicine Nanjing, Jiangsu, China.
FAU - Zhang, Xiaotao
AU  - Zhang X
AD  - Jiangsu Provincial Hospital of Chinese Medicine Affiliated to Nanjing University 
      of Chinese Medicine Nanjing, Jiangsu, China.
FAU - Xu, Yan
AU  - Xu Y
AD  - Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine Nanjing, 
      Jiangsu, China.
FAU - Sun, Zhiling
AU  - Sun Z
AD  - Jiangsu Provincial Hospital of Chinese Medicine Affiliated to Nanjing University 
      of Chinese Medicine Nanjing, Jiangsu, China.
FAU - Ding, Pingan
AU  - Ding P
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University 
      Shijiazhuang, Hebei, China.
FAU - Qian, Xiaoping
AU  - Qian X
AD  - Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing 
      University of Chinese Medicine Nanjing, Jiangsu, China.
AD  - Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School Nanjing, Jiangsu, China.
FAU - Ali, Akbar
AU  - Ali A
AD  - Nishtar Medial College Multan, Punjab, Pakistan.
FAU - Chen, Zilu
AU  - Chen Z
AD  - Center for Molecular Imaging and Nuclear Medicine, School of Radiological & 
      Interdisciplinary Sciences (RAD-X), Soochow University Suzhou, Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20231115
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10695786
OTO - NOTNLM
OT  - CC and CXC chemokine
OT  - Colon adenocarcinoma
OT  - biomarkers
COIS- None.
EDAT- 2023/12/07 06:42
MHDA- 2023/12/07 06:43
PMCR- 2023/11/15
CRDT- 2023/12/07 04:11
PHST- 2023/08/17 00:00 [received]
PHST- 2023/10/15 00:00 [accepted]
PHST- 2023/12/07 06:43 [medline]
PHST- 2023/12/07 06:42 [pubmed]
PHST- 2023/12/07 04:11 [entrez]
PHST- 2023/11/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 Nov 15;13(11):5531-5548. eCollection 2023.